From groundbreaking research at the University of Alabama at Birmingham (UAB) and Southern Research to the Lakeshore Foundation’s commitment to developing novel approaches and technologies for people with chronic health conditions and physical disabilities, there’s no doubt that Birmingham’s commitment to health care is strong. Health Care in Birmingham includes the largest health care cluster in Alabama. Birmingham houses a world class research base, highly skilled workforce and strengths in emerging fields including gene editing and gamma delta t cell immunotherapy.
HEALTH CARE
is the leading employer in Alabama
the world's top 50 pharmaceutical companies
Unique assets to the birmingham region
Click or hover for more information.
Southern Research
- Independent, scientific research organization
- 400+ scientists across four divisions
- Expertise in: drug discovery, drug development, engineering, energy & environment
- Strategic partnerships: NCI, NIH, DOD, NASA
- 20 drugs developed
Harbert Institute for Innovation
- 60 start-up companies
- 2,535 intellectual property disclosures
- 555 issued US patents
- 324 license agreements
- 52 licenses, 48 patents 2017
- $88.9 million total revenue
Center for Clinical and Translational Science
- Transdisciplinary collaborative to reduce the burden of disease and disparities in health outcomes affecting underserved populations
- Only Clinical and Translational Science center in Alabama
- 11 academic and research partners
- $50 Million NIH award: 2019
Lakeshore Foundation
- Comprehensive rehabilitation and sport science research facility
- Developing novel approaches and technologies for persons with chronic health conditions and physical disabilities
- 25 projects ongoing
- Strategic partnerships: NIH, US DOD, CDC, Apple
O'Neal Comprehensive Cancer Center
- Only NCI designated cancer center in AL
- 200+ active clinical trials
- 400 scientists and physician scientists
- 20,000 patients seen annually with 5,000 new cancer patients seen each year
Alabama Drug Discovery Alliance
- 17 programs in development
- 5 key target areas: CNS, oncology, respiratory illness, diabetes, kidney disease
- 4 lead molecules identified
- 2 leads in development
- Oncology target in preclinical evaluation
